CRLBF Cresco Labs Inc. Annual reports only
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1832928 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.5%
TTM net income YoY-81.9%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—
Margins
Gross margin49.5%
Operating margin-4.3%
Net margin-20.6%
FCF margin5.8%
EBITDA margin3.2%
Returns
ROE-33.2%
ROA-10.6%
ROIC (approx.)-2.9%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets78.9%
Debt / equity1.23x
Current ratio2.59x
Interest coverage-0.67x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue5.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $655.85M | $724.34M | $770.88M | $842.68M | $821.68M |
| Cost of revenue | $331.28M | $359.89M | $408.52M | $435.67M | $415.33M |
| Gross profit | $324.57M | $364.45M | $362.37M | $407.01M | $406.35M |
| SG&A expense | $247.45M | $254.84M | $299.17M | $350.65M | $317.80M |
| Operating income | -$27.99M | $107.29M | -$87.82M | -$84.30M | -$217.35M |
| Interest expense | $41.75M | $37.93M | $43.58M | $57.84M | $51.21M |
| Pretax income | -$95.42M | -$10.62M | -$146.90M | -$126.91M | -$256.73M |
| Income tax | $44.62M | $49.87M | $32.95M | $88.94M | $40.11M |
| Net income | -$135.41M | -$74.44M | -$175.52M | -$212.05M | -$319.60M |
| EBITDA | $20.73M | $166.39M | -$25.31M | -$32.37M | -$178.71M |
| EPS (basic) | -0.38 | -0.22 | -0.54 | -0.71 | -1.22 |
| EPS (diluted) | -0.38 | -0.22 | -0.54 | -0.71 | -1.22 |
| Weighted avg. shares (diluted) | 355.01M | 345.47M | 323.82M | 298.16M | 262.33M |
| Balance sheet | |||||
| Cash & equivalents | $57.90M | $137.56M | $108.52M | $121.51M | $223.54M |
| Receivables | $37.89M | $51.56M | $51.07M | $56.49M | $43.38M |
| Inventory | $98.67M | $83.34M | $107.79M | $134.61M | $136.64M |
| Current assets | $259.27M | $294.26M | $278.09M | $326.05M | $421.75M |
| PP&E, net | $327.19M | $344.85M | $368.31M | $379.72M | $369.09M |
| Goodwill | $208.17M | $283.48M | $279.70M | $330.56M | $446.77M |
| Intangibles | $275.34M | $293.99M | $296.97M | $407.59M | $437.64M |
| Total assets | $1.20B | $1.36B | $1.36B | $1.58B | $1.78B |
| Current liabilities | $100.18M | $94.34M | $200.24M | $255.87M | $288.39M |
| Short-term debt | $3.30M | $2.61M | $2.00M | $10.98M | $19.93M |
| Long-term debt | $417.10M | $460.75M | $497.71M | $476.89M | $465.08M |
| Total debt | $420.39M | $463.36M | $499.72M | $487.87M | $485.01M |
| Total liabilities | $944.80M | $967.18M | $930.40M | $996.01M | $982.73M |
| Shareholders' equity | $340.45M | $474.85M | $505.69M | $627.04M | $755.55M |
| Net debt | $362.49M | $325.80M | $391.20M | $366.36M | $261.46M |
| Cash flow statement | |||||
| Operating cash flow | $72.89M | $132.48M | $58.56M | $18.74M | $14.49M |
| Capital expenditure | $35.14M | $19.49M | $55.38M | $83.03M | $93.88M |
| Free cash flow | $37.75M | $112.99M | $3.18M | -$64.28M | -$79.39M |
| Investing cash flow | -$40.70M | -$25.23M | -$44.59M | -$36.58M | -$163.93M |
| Financing cash flow | -$82.09M | -$71.48M | -$26.91M | -$86.64M | $235.00M |
| Depreciation & amortization | $48.71M | $59.10M | $62.51M | $51.93M | $38.64M |
| Stock-based compensation | $11.23M | $14.16M | $16.36M | $23.22M | $27.54M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.